1. Generics Bulletin
  2. >>Business
  3. >>Deals

Amneal Invests Up To $200m In Manufacturing Under Metsera GLP-1 Pact

Collaboration Follows ‘Highly Competitive’ Phase I Data For Metsera Asset

 
• By Dean Rudge

Amneal will lend its expertise in product development and manufacturing under a collaboration with obesity and metabolic disorders start-up Metsera – the latest in a recent string of deals involving the highly sought-after GLP-1 analogs.

Magnifying glass over GLP-1 on blackboard
• Source: Shutterstock

Amneal was credited for its product development and manufacturing capabilities, including in-house API and sterile fill-finish manufacturing, as the US-based firm penned a collaboration agreement with New York City start-up Metsera to enable the efficient development and large-scale supply of a portfolio of new obesity medicines globally.

Under the terms of the agreement, Amneal will serve as Metsera’s preferred supply partner for developed markets, including the US and Europe, while also being granted a license to commercialize Metsera’s products in select emerging markets,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business